Lauren Michelle Madigan, MD, FAAD
SESSIONS
F072 The Morbilliform Eruption: Differentiation and Treatment of Viral, Low-risk Drug, Severe Cutaneous Adverse Reactions, and GVHD
Mar 9, 2024
•
3:30 PM - 12:00 AM
•
Room 6C
HANDOUTS
Login to view handouts
DISCLOSURES
Blueprint Medicines – Advisory Board(Honoraria); Cogent Biosciences – Advisory Board(Honoraria); GlaxoSmithKline Immunology – Data Safety Monitoring Board(Fees);